Protective effect of the lazaroid U74006F in cold ischemia‐reperfusion injury of the liver

Lipid peroxidation may play a major role in the loss of liver graft viability after prolonged cold ischemia and reperfusion injury. The lazaroid compound U74006F is a potent inhibitor of lipid peroxidation, and this study was designed to evaluate the efficacy of this compound in preventing cold ischemia–reperfusion damage in three different models: pig endothelial cells in culture, ex vivo isolated pig liver perfusion and orthotopic transplantation of syngeneic rat livers. The addition of U74006F to University of Wisconsin preservation solution significantly prolonged endothelial cell viability after 48 and 72 hr of cold ischemia and reoxygenation (p < 0.01). Donor pigs were injected with vehicle or U74006F (4.5 mg/kg) before liver harvest. After 24 hr of cold storage in University of Wisconsin solution, the livers were perfused with pig blood for 180 min in an isolation chamber. Measurements of liver function parameters, including AST, ALT, bile production, superoxide anion and phospholipase A2 release, were assessed every 60 min. Although bile production was similar in the U74006F‐treated and control groups, significant decreases of AST and ALT levels (p < 0.01) in the perfusate of the livers from treated donors were observed. In addition, the U74006F group displayed significantly reduced release of superoxide anion and phospholipase A2 compared with these parameters in the untreated group (p < 0.05 and p < 0.01, respectively). In the last model, donor rats were treated with U74006F before harvest; the rat liver grafts were preserved in cold University of Wisconsin solution for 24 hr and then transplanted into recipient rats. The number of liver graft recipients that survived 7 days after transplantation was significantly larger (p < 0.001) in the group of recipients of U74006F‐treated livers. Furthermore, this group showed significantly lower levels of lipid peroxides in liver tissues (p < 0.01) and AST and ALT release (p < 0.05) compared with the control group at 2 and 7 days after transplantation. We conclude that U74006F is effective in enhancing the resistance of the liver to damage due to cold ischemia–reperfusion injury and that the use of this compound may improve early liver graft function after transplantation. (Hepatology 1994;19:418–425).